News

The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease. Auvelity is now the only FDA-approved treatment for Alzheimer’s-related agitation that is not classified as an antipsychotic, according to the Alzheimer’s Association. “For…

The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73) were sustained over nearly three years, according to new analysis from the treatment’s developer, Anavex Life Sciences. Patients treated with the investigational oral medication in a Phase 2b/3 study…

Researchers are calling for more studies to determine whether lymphovenous anastomosis (LVA), a surgical procedure that helps clear molecular waste from the brain, might benefit people with Alzheimer’s disease. “LVA represents a novel therapeutic strategy that may complement existing treatments, offering new hope for addressing the [disease biology] of…

The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an approved treatment for early Alzheimer’s disease. Under its current approval, patients are first given the therapy as infusions into the…

The U.S. Food and Drug Administration (FDA) granted priority review to an application from Axsome Therapeutics seeking approval of its oral therapy AXS-05 to treat agitation related to Alzheimer’s disease, and expects to decide by April 30, the company said. Priority review shortens the FDA’s review time to six…

Semaglutide, an anti-diabetic medication, did not slow Alzheimer’s disease progression in two large, placebo-controlled Phase 3 clinical trials sponsored by its developer, Novo Nordisk. As a result, the planned one-year extension period for both will be stopped. The EVOKE (NCT04777396) and…

Health Canada has conditionally approved Leqembi (lecanemab) for certain adults with early Alzheimer’s disease, making it the first treatment approved in Canada that targets an underlying cause of early Alzheimer’s by removing toxic amyloid-beta proteins from the brain. The therapy, co-developed by Eisai and Biogen, was cleared for…

The European Commission has approved Eli Lilly‘s monthly infusion therapy Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease. The treatment targets sticky protein clumps, or amyloid plaques, in the brain and is specifically indicated for people in the early stages of the disease who meet specific…

The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, announced by co-developers Biogen and Eisai, applies to those who first receive at least 1.5 years of the intravenous version. The approval…

September is World Alzheimer’s Month, and the global Alzheimer’s disease community is looking to raise awareness and combat stigma related to Alzheimer’s and other forms of dementia. “This September, we are … advocating for greater awareness and understanding around dementia in a direct campaign that encourages people to ask…